The epitope recognized by monoclonal antibody MAb215 generated previously against Drosophila melanogaster RNA polymerase II was mapped to amino acid residues 806-820 of the largest, 215 kDa, subunit located in a region conserved within the largest subunits of pro-and eukaryotic RNA polymerases. The affinities of MAb215 and of a recombinant single-chain Fv fragment (scFv215) were determined for binding to the enzyme as well as the fusion protein and synthetic peptides used for epitope mapping. In addition, amino acid residues of the epitope important for binding to MAb215 were identified using peptides carrying single amino acid substitutions. The epitope is not involved in the polymerization reaction or the DNA unwinding process since no inhibitory effects of the monoclonal antibody were observed in nonspecific in vitro transcription using denatured calf thymus DNA or double stranded oligo dC-tailed T7 DNA as template. In contrast, MAb215 inhibits accurate in vitro transcription from the Krüppel gene promoter and from the adenovirus-2 major late promoter. Preincubation of template DNA with the nuclear extract had no effects on inhibition supporting the notion that the epitope does not participate directly in the formation of preinitiation complexes.The same inhibitory effects were observed using scFv215. The results provide further evidence that recombinant antibody fragments produced in Escherichia co//possess the same specificity and similar affinity as their parental antibodies and demonstrate that scFv fragments are useful tools for analysis of transcriptional processes.
Introduction
Transcription of eukaryotic genes is accomplished by three nuclear RNA polymerases composed of two large subunits with molecular weights above 120000 and several smaller subunits. The two large subunits of the eukaryotic enzymes are the structural and functional equivalents of the ' and subunit of the coll RNA polymerase, which form the major part of the catalytic site including regions involved in binding to the DNA template, the nascent RNA and the nucleotide substrates (for review see: Sawadogo and Sentenac, 1990) . The first steps in transcription initiation of eukaryotic genes involve a complex interaction of RNA polymerase, several general transcription factors and promoter elements resulting in the formation of preinitiation complexes, which are able to initiate RNA synthesis accurately and efficiently (Conaway and Conaway, 1991; Weinmann, 1992) . The transition from initiation to elongation occurs by dissociation of the RNA polymerase molecule from the initiation complex.
Various biochemical and genetic approaches have been employed to identify and to characterize regions of the RNA polymerase subunits involved in the transcriptional process in vivo and in vitro (for review see: Sawadogo and Sentenac, 1990) . In addition, immunological studies using monoclonal antibodies were applied to identify functionally important regions of E coli RNA polymerase subunits (Nikiforov et a/., 1983; Rockwell et a/., 1985; Luo and Krakow, 1992 , and references therein) and of eukaryotic RNA polymerase subunits (for review see: .
Previously a mouse monoclonal antibody (clone 3; designated here MAb215) was generated in our laboratory against RNA polymerase II of Drosophila melanogaster (Krämer et a/., 1980) . This antibody of the lgG1 class reacts with transcriptionally active enzyme and can be used to visualize the distribution of RNA polymerase II on polytene chromosomes. A cross-reaction with RNA polymerase II of mammals showed that the antibody recognizes a structurally conserved epitope (Krämer and Bautz, 1981; Dubois etal., 1994) . Inhibitory effects of the monoclonal antibody on transcription in vivo was demonstrated by microinjection of the antibody into amphibien oocytes resulting in retraction of lampbrush loops, an effect which is more rapidly observed using polyclonal immunoglobulins directed against RNA polymerase II (Bona etal., 1981) . In immunoblot analyses the antibody reacted strongly with the largest subunit and with variable intensities with the second-largest subunit (Kr mer etal., 1980; Kramer and Bautz, 1981) , under stringent conditions, however, only the largest subunit bound MAb215 (Boes, 1981) .
In order to obtain further information about the structure and function of the region recognized by MAb215 we identified and characterized the epitope and we analysed the effects of the antibody on in vitro transcription from nonspecific as well as promoter-containing templates. Furthermore, we used a recombinant single-chain antibody fragment (scFv215) derived from MAb215 for functional studies and for a quantitative evaluation of the affinities to RNA polymerase II as well as a fusion protein and a peptide containing the epitope sequence in order to analyse whether a recombinant antibody fragment can substitute MAb215 in functional assays.
Results

Epitope Mapping of MAb215
Immunoblot assays with MAb215 IgG (5 ,ug/ml) purified from ascites fluid showed that the antibody preparation used in this study reacts exclusively with the largest, 215 kDa, subunit of RNA polymerase II (data not shown). In order to localize the epitope we analysed binding of the monoclonal antibody to -galactosidase fusion proteins expressing overlapping fragments of the largest subunit (215-1 to 215-11; see Figure 1 ). Immunoblotting experiments with these constructs showed a reaction of MAb215 only with fusion protein 215-5 expressing amino acids 725-897, while no binding was observed to the adjacent fusion proteins 215-4 (amino acids 432-775) and 215-6 (amino acids 817-1172) (Figure 1 ). This finding indicates that the epitope is located in a region around amino acid residues 776-816. To further identify the exact position of the epitope we tested overlapping synthetic peptides with a length of 15 amino acids covering amino acids 766-825 (Figure 2 ). The peptides were coupled to BSA and were analysed in dot blot assays for binding of MAb215. Only peptide 9 (215-P9) showed a positive reaction, while peptides 7,8, and 10, which overlap with the P9 sequence did not react. To avoid possible artifacts due to inaccessibility of carrier-bound peptides other than P9 we also analysed MAb215 in a competition ELISA. MAb215 was preincubated in solution with uncoupled peptides in excess and was then tested for binding to solid-phase bound fusion protein 215-5 by ELISA. In this assay only peptide 9 showed complete inhibition of binding, while all other peptides including the overlapping neighbors had no effect on binding of MAb215 to the fusion protein (data not shown). These experiments indicate that most of peptide 9 (residues 806-820; DYGPESRGFVENSYL) is necessary for binding of the monoclonal antibody.
The epitope is located within region F, which is one of eight regions (A-H) highly conserved among the largest subunits of RNA polymerases (Young, 1991 ; see Figure 1 ). A comparison of the epitope with the corresponding regions of the largest subunits of other RNA polymerases shows a high degree of conservation within RNA polymerase II subunits of a variety of eukaryotic organisms and a lesser similarity to RNA polymerases I and III ( Figure 3 ). Similarity is also observed with archaebacterial subunits, but not with the rpoCgene products of E. coli and chloroplast RNA polymerases. 
Methanobacterium E Halobacterium Q Sulfolobus R Fig. 3 Sequence Comparison of the MAb215 Epitope. The sequence of the epitope (= peptide 9) recognized by MAb215 was aligned with the corresponding sequences of the largest subunits of eukaryotic RNA polymerases I, II, and III and archaebacterial RNA polymerases. Sequences were from the SWISS-PROT protein sequence database.
Identification of Amino Acid Residues Important for Antigen-Antibody Interaction
In order to identify amino acid residues within the MAb215 epitope which are important for binding we analysed synthetic peptides with single amino acid substitutions (P12-P26, see Table 1 ). The amino acids of the P9 sequence were either substituted by glycine or, where glycines were present, by alanine. The affinity constants for binding of MAb215 to these peptides were determined by competition ELISA using peptide concentrations between 10" 3 M and 10~7M. This analysis identified five amino acid residues essential for binding: two amino acid substitutions resulted in a complete loss of binding under these assay conditions (E816G, N817G) and three further substitutions reduced the affinity by a factor of 100-500 (P809G, R812G, F814G). The remaining substitutions had no effects on binding (G808A, G813A, Y819G) or resulted only in a minor reduction of binding by a factor of 5-30 (D806G, Y807G, E810G, S811G, V815G, S818G, L820G). 
Affinities of MAb215 and a Single-Chain Antibody Fragment (scFv215)
After preincubation of MAb215 with the various antigens to equilibrium the affinity constants for binding to RNA polymerase II, fusion protein 215-5, and peptide P9 were determined by competition ELISA (Friguet et a/., 1985) using solid-phase bound fusion protein fp215-5 for detection of free binding sites. The antibody binds with high affinity to the fusion protein and to lesser extend to RNA polymerase II and the synthetic peptide (Table 2) .
In order to analyse whether a recombinant antibody fragment can substitute MAb215 with respect to specificity and affinity the variable regions of MAb215 were expressed as single-chain Fv fragment. The coding regions of the variable light and heavy subunit domain of MAb215 were prepared from hybridoma cells and were assembled into a single-chain fragment introducing a sequence encoding a (Gly 4 Ser) 3 peptide linker. Soluble fragments (scFv215) were produced by cloning of the fragment into expression vector pOPE51 (Kipriyanov et al., 1994) . ScFv215 was purified from periplasmic preparations by immobilized metal affinity chromatography (IMAC). The specificity of scFv215 was confirmed by ELISA and immunoblotting experiments with RNA polymerase II and various fusion proteins (data not shown). Purified scFv215 was used for determination of the affinity constants by competition ELISA. The affinities of the recombinant antibody fragment are comparable to that of its parental antibody except for an about 3-4 fold weaker binding to peptide P9 (Table 2) .
Effects of MAb215 on Nonspecific In Vitro Transcription
In order to investigate whether MAb215 has inhibitory effects on RNA polymerase II transcription we first analysed the effects of the antibody in nonspecific in vitro transcription assays. Purified RNA polymerase II was preincubated for one hour on ice with varying amounts of MAb215 IgG or control mouse IgG and the transcriptional activity was analysed under standard conditions using denatured calf thymus DNA as template. This assay showed that neither MAb215 nor control IgG inhibit nonspecific transcription even at a molar ratio of antibody to enzyme of about 350 (500 Lig/ml), indicating that binding of MAb215 to the enzyme has no influence on catalytic activity (data not shown). In order to analyse whether MAb215 inhibits transcription of double stranded DNA, similartranscription assays were performed using a double stranded oligo dCtailedT7 DNA template (Kadesch and Chamberlin, 1982) . Preincubation of RNA polymerase II with MAb215 even at molar excess of as high as 425 fold (500 ,ug/ml) resulted in no loss of activity (data not shown).
Effects of MAb215 on Specific In Vitro Transcription
We next analysed the effects of MAb215 on promoter-directed in vitro transcription. For this purpose we used the well-characterized Drosophila Kr ppel gene promoter. Transcription from this promoter initiates at several sites over a region of 10 nucleotides (Kerrigan et al., 1991) resulting in primer extension products with lengths of 74,727 71, 69/68, and 65 nucleotides with the major start sites at positions 72 and 69, respectively (see Figure 4A ). Preincubation of Drosophila embryo nuclear extract with MAb215
for one hour at 0 °C resulted in inhibition of accurate transcription. Preincubation with 5 ,ug MAb215 reduced accurate transcription to about 20% residual activity as determined by scanning densitometry of the primer extension products, while control mouse IgG at the same concentration showed no inhibition ( Figure 4A ). Interestingly, some additional weak bands became visible 10 to 15 nucleotides downstream from the major start sites at positions 62 and 58/57. Inhibition of specific transcription by preincubation of nuclear extracts with MAb215 was also observed using the adenovirus-2 major late promoter ( Figure  4B ). In this case, accurate transcription was reduced to about 16% on preincubation with 5 μg MAb215 per assay.
* $ s * Nuclear extracts of Drosophila embryos were preincubated with MAb215 for 1 h on ice at varying concentrations (1 μ9~5 μο/ assay) and accurate in vitro transcription from the Kruppe/ gene promoter (Kr) or the adenovirus-2 major late promoter (Ad) was analysed by primer extension (A + B). IgG from nonimmunized mice was included as negative control. Incubation of nuclear extracts with a-amanitin (3 χ 10~7Μ) results in complete inhibition of transcription. Inhibition of accurate transcription from the Kr ppel gene promoter (C) and the adenovirus major late promoter (D) was also observed using scFv215 at a concentration of 5 \ig/ assay. A purified scFv recognizing the hapten phenyl-oxazolone was used as negative control.
To test whether the inhibitory effects are caused by inhibition of the formation of preinitiation complexes we incubated the nuclear extracts with template DMA for 30 minutes at room temperature before adding antibodies. Kadonaga (1990) had shown that formation of preinitiation complexes at the Krüppel gene promoter occurs at room temperature with a f 1/2 of about 3 minutes and that after 20-30 minutes all complexes are formed. Preincubation of template DMA with nuclear extract, however, had no effects on inhibition of accurate transcription initiation from the Krüppel gene promoter and from the adenovirus-2 major late promoter by MAb215 (data not shown).
Effects of scFv215 on In Vitro Transcription
No inhibitory effects were found analysing scFv215 in nonspecific transcription assays using denatured calf thymus DMA as template (data not shown). In contrast, as observed for MAb215, scFv215 inhibited specific transcription from the Krüppel gene promoter and the adenovirus-2 major late promoter ( Figure 4C and 4D). Preincubation of nuclear extract with scFv215 at 5 4 ug/ assay resulted in reduction of accurate transcription to about 20% from both promoters. The additional bands downstream of the correct transcription start sites which became visible in inhibitory assays of MAb215 at the Krüppel gene promoter were not observed with scFv215.
Discussion
The epitope recognized by monoclonal antibody MAb215 was mapped within the largest subunit of RNA polymerase II. The epitope is located in an evolutionary conserved region (region F) consistent with the observation that MAb215 cross-reacts with the largest subunits of RNA polymerase II of other species (Krämer and Bautz, 1981) .
MAb215 recognized a recombinant fusion protein with high affinity whereas binding of MAb215 to RNA polymerase II is about 100 fold weaker, indicating that the epitope is probably only partially accessible in the native enzyme. Peptide P9 represents the minimal binding site of MAb215. P9 itself has only a relatively weak affinity for the antibody. It has been shown that reacting peptides mimic only the primary interaction site (Barlow et al., 1986) and thus have a reduced affinity compared with the complete antigen. Interestingly, no other parts of the largest subunit bind to the monoclonal antibody in immunoblotting experiments. However, given the differences between the binding affinities for fusion protein 215-5 and peptide P9, this finding indicates that parts of fusion protein 215-5 outside the P9 sequence must contribute indirectly to the strength of antibody-antigen interaction, e.g. by stabilizing a defined secondary or tertiary structure. This finding is in accordance with a concept of protein antigenicity involving an active, attractive contribution of an 'energetic' epitope formed by the energetically most important residues and the passive surface complementarity contributed by the surrounding contact area .
The analysis of binding of MAb215 to peptides with single amino acid substitutions confirmed that at least amino acids 809-817 of the P9 sequence are necessary for minimal binding. This length of the epitope is consistent with X-ray crystallographic studies showing that protein epitopes are build from about 15-22 amino acids, however, not necessarily in a linear context (for review see Laver et al., 1990; Davies et al., 1990) . A number of five amino acid substitutions having significant effects on binding is in agreement with data obtained for various antibody-protein complexes which showed that only about 5-6 amino acids contribute primarily to the binding energy (Novotny, 1989; Novotny et al., 1989; Kelley and O'Connell, 1993) .
The binding data of soluble scFv215 showed that the recombinantly expressed antibody is folded into an active molecule capable of binding to RNA polymerase II and the fusion protein with affinities comparable to that of the original antibody. Similar affinities of binding of scFv215 to fusion protein 215-5 were also demonstrated previously for size-fractionated mono-and divalent forms of the antibody fragment prepared by renaturation of protein isolated from inclusion bodies (Kipriyanov et al., 1994) . Binding to peptide P9, however, is about 3-4 fold weaker, indicating that some small structural differences must exist between MAb215 and scFv215 affecting binding to the minimal binding site. Various authors have shown that scFv fragments can bind with the same specificity and affinity to their antigens as the original antibody (Batra et al., 1990; Cheadle et al., 1992; Freund et al., 1993; Glockshuber et al., 1990; Pantoliano etal., 1991) . In contrast, it has also been reported that scFv fragments exhibit lower affinities than the parent antibodies (Malby et al., 1993; Huston et al., 1988) and that the length and composition of the linker sequence effects the strength of binding and stability of the fragment (Whitlow et al., 1993) .
No inhibitory effects were detected with MAb215 or scFv215 in nonspecific in vitro transcript ion assays using denatured calf thymus DNA as template. Since the assay measures only the catalytic activity of RNA polymerase II under elongation conditions, this finding indicates that the epitope recognized by MAb215 participates neither in the polymerization reaction nor in transcription initiation from nonpromoter sites. Furthermore, the results obtained from nonspecific in vitro transcription using double stranded oligo dC-tailed DNA as template showed that MAb215 has no inhibitory effects on the process of unwinding duplex DNA.
Alpha-amanitin is a specific inhibitor of the translocation step after formation of a phosphodiester bond by RNA polymerase II (Vaisius and Wieland, 1982) , and aamanitin-resistance mutations were found to reside exclusively in the largest subunit (Greenleaf, 1983) . One aamanitin resistance mutation was previously localized in the conserved region F of the largest subunit of mouse RNA polymerase II (Asn at position 793 to Asp) indicating that region F is involved in the transiocation step (Bartolomei and Corden, 1987) . The corresponding position in the Drosophila sequence (amino acid residue 784) is located relatively close to the MAb215 epitope (amino acid residues 806-820). One further -amanitin resistant mutation was recently identified in the largest subunit of Drosophila RNA polymerase II. This mutation residing at position 741 changes a highly conserved Arg to His (Chen et al., 1993) and is located near the reported mouse mutation. Binding of MAb215 to region F, however, has no inhibitory effects on the catalytic activity suggesting that only parts of region F participate in the transiocation reaction.
Our data obtained from promoter-directed in vitro transcription using the Krüppel gene promoter and the adenovirus-2 major late promoter showed that MAb215 inhibits accurate transcription from both promoters. This inhibitory effects were confirmed with a recombinant singlechain Fv fragment exhibiting the same specificity and affinity. Inhibition of specific transcription is consistent with the results of Bona et al. (1981) demonstrating inhibitory effects of MAb215 on in vivo transcription by microinjection of MAb215-lgG into amphibian oocytes. Inhibitory effects of specific in vitro transcription from various promoters but not of nonspecific transcription were also described for monoclonal antibodies recognizing the CTD (Carboxy-terminal heptapeptide repeat domain) (Dahmus and Kedinger, 1983; Dahmus et al., 1988; Labourn and Dahmus, 1989; Moyle et al., 1989) . The inhibitory potential of a monoclonal antibody (J352) directed against the CTD on transcription initiation of HeLa nuclear extracts from the adenovirus-2 major late promoter is strongly reduced by preincubation of template DMA with nuclear extract (Moyle et al., 1989) . Our studies showed that preincubation of nuclear extracts with template DMA in the absence of any nucleotides have no effects on the inhibitory potential of MAb215 on transcription initiation. This finding indicates that the MAb215 epitope is still accessible after formation of preinitiation complexes. Therefore, we suggest that this region of the largest subunit does not participate directly in interaction of RNA polymerase II with transcription factors and that binding of MAb215 to the enzyme inhibits another step of the initiation reaction. Complete preinitiation complexes are formed by RNA polymerase II, transcription factors and template DNA in the absence of ATP and any other nucleotides, which become then converted into activated complexes in the presence of ATP and additional factors (Conaway and Conaway, 1991; Drapkin and Reinberg, 1994) . In a second step these activated complexes are converted into elongation complexes. The region containing the MAb215 epitope might be involved in one of these initiation reactions but binding of MAb215 might also inhibit a step in the early elongation reaction.
Materials and Methods
Materials
A monoclonal antibody against Drosophila RNA polymerase II (clone 3, designated here MAb215) was generated previously in our laboratory (Kramer et al., 1980) . Purified IgG of this antibody was kindly provided by Progen (Heidelberg, Germany) and purified mouse IgG from non-immunized animals used as negative control was purchased from Dianova (Hamburg, Germany). Monoclonal antibody 9E10 recognizing a c-myc epitope was purchased from Cambridge Reseach Biochemicals (Cambridge, U.K.). A recombinant scFv fragment recognizing the hapten phenyl-oxazolone was kindly provided by Dr. G. Winter (Cambridge, U.K.). Alpha-amanitin and deoxyribonucleotides were purchased from Boehringer-Mannheim (Germany). Polynucleotide kinase was obtained from Biolabs (Schwalbach, Germany) and terminal deoxynucleotidyltransferase was purchased from Promega (Heidelberg, Germany). T7 DNA was purchased from Sigma. [ 
Purification of RNA Polymerase II, Fusion Proteins and Peptides
RNA polymerase II was purified from Drosophila embryos as described by Seifarth et al. (1991) with minor modifications. Betagalactosidase and ß-galactosidase fusion proteins expressing fragments of the largest subunit of Drosophila RNA polymerase II were purified from inclusion bodies as described and were solubilized in 10mMTris-HCI pH 7.5,1 % SDS. Synthetic peptides were synthesized in the laboratory of Dr. R.W. Frank (ZMBH, Heidelberg, Germany). Protein concentrations were determined by the methods of Lowry et al. (1951) or Bradford (1976) and the concentrations of peptide solutions were determined by the biuret reaction. Purity of fusion protein and RNA polymerase II was determined by scanning densitometry of Coomassie blue stained polyacrylamide gels. Fusion protein 215-5 used for determination of binding constants was dialyzed against PBS pH 7.3 for 2 days.
Coupling of Peptides to BSA
BSA and synthetic peptides were diluted in PBS pH 7.3 or in case of peptides P1, P2 and P10 in PBS containing 50% dimethylformamide. Peptides were coupled to BSA by incubation with 0.1 % glutaraldehyde (Sigma, Heidelberg, Germany) for 1 h at room temperature. Free reactive groups were blocked by incubation with 200mM glycine in PBS pH 7.3 and unbound peptides were separated by dialysis against PBS (Harlow and Lane, 1988) .
Cloning and Expression of Single-Chain Antibody Fragment scFv215
mRNA was purified from hybridoma cells expressing monoclonal antibody MAb215 using mRNA Quick-prep kit (Pharmacia, Freiburg, Germany). The coding sequences of the variable light and heavy chain were assembled into single-chain fragments and were cloned into pCANTABS for expression as phage display antibody using a phage display kit (Pharmacia). Positive clones were selected by one round of panning against fusion protein 215-5 (10 ng/ml). Sequencing of the variable domains was performed using aT7 sequencing kit (Pharmacia) and two primers corresponding to the 5' and 3' flanking sequences of pCANTABS. For phage ELISA microtitre plates were coated with antigens at a concentration of 10 g/ml and remaining binding sites were blocked with PBS pH 7.3, 0.1 % BSA. The ELISA was performed according to the manufacturer's protocol (Pharmacia).
For expression of soluble scFv fragments the single-chain fragment was cloned into pOPE51 which expresses a c-myc tag and a histidine tail at the C-terminus (Kipriyanov et a/., 1994) . Cells were grown in 112xTY medium containing 100 ng/ml ampicillin at room temperature to an ODeoo of 1.0 and production of scFv was induced by addition of 20 μΜ IPTG. After 3 h cells were harvested and resuspended in 50 ml buffer P (30 mM Tris-HCI pH 8.0,1 mM EDTA, 20% sucrose) and were incubated for 20 min on ice. After centrifugation at 4 000 χ g for 10 min, cells were resuspended into 50 ml 5mM MgSO 4 and were incubated for 20 min on ice. After centrifugation for 10 min at 6000 χ g the supernatants of the two incubations were pooled and cleared by centrifugation at 30000 χ g for 30 min. The supernatant was dialyzed against buffer I (50 mM sodium phosphate pH 8.0, 300 mM NaCI) containing 10 mM imidazole and was applied to nickel-chelate affinity chromatography using Ni-NTA resin (Diagen). Proteins were eluted with a 10-150 mM linear imidazole gradient (200 ml) in buffer I and analysed on 12% or 15% polyacrylamide gels by SDS-PAGE (Laemmli, 1970) . Detection of scFv fragments were carried out by immunoblotting experiments as described (Liu et a/., 1993) with an anti-c-myc mouse monoclonal antibody (9E10) recognizing the c-myc tag sequence at the C-terminus of the scFc or polyclonal rabbit serum A (D bel et a/., 1992 and 1993) directed against the N-terminal core sequence QVQLQ of the correctly processed V H chain. Large quantities of highly concentrated scFv215 (-1 mg/ml) used in transcription inhibition assays were prepared from inclusion bodies as described (Kipriyanov et a/., 1994) and purified by I MAC.
Determination of Binding Constants
The dissociation constants of binding of monoclonal antibody MAb215 and of purified scFv215 to purified RNA polymerase II, bacterially expressed fusion protein 215-5 (aa 725-879 of the largest subunit of RNA polymerase II), and synthetic peptides were determined by competitive ELISA as described by Friguet et al. (1985) . Antibody solutions were adjusted to a concentration of 10~9 M for determination of binding to RNA polymerase II and peptides and to a concentration of 4 χ 10~Ί Ο Μ for binding to fusion protein 215-5 and were preincubated with antigens at varying concentrations overnight at room temperature (fp 215-5 and P9) or at + 4 °C (RNA polymerase II) in PBS pH 7.3,0.05 % BSA. Microtitre plates were coated with fusion protein 215-5 at a concentration of 1.5 μg/ml in sodium hydrogen carbonate buffer pH 9.6. After blocking with PBS pH 7.3,0.5 % BSA, plates were incubated with preincubated antibodies for 30 min at room temperature. Bound MAb215 was detected using peroxidase-conjugated goat anti-mouse immunoglobulins (Dianova) and bound scFv215 was detected using monoclonal antibody 9E10 and subsequently peroxidase-conjugated goat anti-mouse antibodies (Dianova).
Gel Electrophoresis and Immunoblotting
Proteins were analysed on SDS-polyacrylamide gels according to Laemmli (1970) under reducing conditions and were either stained with Coomassie brilliant blue R-250 or transferred onto nitrocellulose sheets by semidry blotting. Remaining binding sites on the filter were blocked by incubation in PBS pH 7.3,0.3% Tween-20. Filters were then incubated for 1 h with polyclonal serum against Drosophila RNA polymerase II (diluted 1:5000 in PBS pH 7.3, 0.3% Tween-20) or with the monoclonal antibody MAb215 in a final concentration of 5 μg/ml or 0.5 μg/ml, respectively. Bound antibodies were detected by incubation with peroxidase-conjugated secondary antibodies (Dianova) using 4-chloro-1-naphthol/H 2 O 2 as substrate.
In Vitro Transcription
Nonspecific in vitro transcription assays were performed as described (Greenleaf and Bautz, 1975) using denatured calf thymus DNA or double stranded oligo dC-tailed T7 DNA (Kadesch and Chamberlin, 1982) as template. dC-tailing ofT7 DNA was performed according to Kadesch and Chamberlin (1982) using terminal deoxy-nucleotidyltransferase, dCTP and the following reaction buffer (100 mM cacodylate pH 6.8, 1mM CoCI 2 , 0.5 mM DTT, 500 μg/ml BSA). For transcription assays with calf thymus DNA 0.5 μg RNA polymerase II were incubated with the template DNA in 100 μΐ transcription buffer (50 mM Tris-HCI pH 7.6,150 mM KCI, 2mM MgCI 2 , 0.5 mM each ATP, CTP and GTP, 1 mM DTT, 20 μΜ [ 3 H]UTP) for 20 min at 30 °C. Transcription assays with oligo dCtailed DNA were performed in 50 μΐ transcription buffer containing 100 mM (NH 4 ) 2 S0 4 instead of KCI and 0.2 μς RNA polymerase II. Transcripts were precipitated with 5% TCA for 15 min on ice and were filtered onto Whatman GF/A filters. Incorporated [ 3 H]UTP was measured by scintillation counting. For inhibition assays the RNA polymerase II preparation was preincubated with varying amounts of purified immunoglobulins for 1 h on ice. Specific in vitro transcription of Drosophila embryo nuclear extracts from the Kr ppel gene promoter and the adenovirus-2 major late promoter was performed using an eukaryotic in vitro transcription kit (Stratagene, Heidelberg, Germany). Transcription start sites were determined by primer extension analyses as described by the manufacturer's protocol using 32 P-endlabelled oligonucleotides as primers. Primer extention products were analysed on sequencing gels with a known DNA as size marker. Inhibition of specific transcription by the monoclonal antibody was analysed by preincubation of the nuclear extract with purified IgG for 1 h on ice. In order to analyse the inhibitory effects of MAb215 after formation of preinitiation complexes, template DNA was preincubated with nuclear extract in transcription buffer for 30 min at room temperature in the absence of nucleotides (Kadonaga, 1990 ) before incubation with antibodies for 1 h on ice. Unless indicated otherwise all experiments were done in duplicate.
